Literature DB >> 19847626

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.

Yan Yang1, Michael D Tsifansky, Chia-Jung Wu, Hae In Yang, Gudrun Schmidt, Yoon Yeo.   

Abstract

PURPOSE: To achieve efficient antibiotic delivery to the cystic fibrosis (CF) airway using a single inhalable powder co-encapsulating a mucolytic and an antibiotic.
METHODS: Inhalable dry powders containing deoxyribonuclease and/or ciprofloxacin (DNase, Cipro, and DNase/Cipro powders) were produced by spray-drying with dipalmitylphosphatidylcholine, albumin, and lactose as excipients, and their antibacterial effects were evaluated using the artificial sputum model.
RESULTS: All powders showed mass median aerodynamic diameters below 5 microm. Both drugs were loaded in the dry powders without loss in quantity and activity. Dry powders containing DNase significantly decreased the storage modulus of the artificial sputum medium in less than 30 min. When applied to artificial sputum laden with Pseudomonas aeruginosa, Cipro/DNase powder showed better antibacterial activity than Cipro powder. The higher activity of the Cipro/DNase powder is attributable to the mucolytic activity of DNase, which promotes penetration of the dry powder into the artificial sputum and efficient dissolution and diffusion of ciprofloxacin.
CONCLUSIONS: Inhalational delivery of antibiotics to the CF airway can be optimized when the sputum barrier is concomitantly addressed. Co-delivery of antibiotics and DNase using an inhalable particle system may be a promising strategy for local antipseudomonal therapy in the CF airway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19847626     DOI: 10.1007/s11095-009-9991-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  51 in total

1.  Comparison of particle sizing techniques in the case of inhalation dry powders.

Authors:  C Bosquillon; C Lombry; V Preat; R Vanbever
Journal:  J Pharm Sci       Date:  2001-12       Impact factor: 3.534

2.  Determination of Pulmozyme (dornase alpha) stability using a kinetic colorimetric DNase I activity assay.

Authors:  Ralf Lichtinghagen
Journal:  Eur J Pharm Biopharm       Date:  2006-05-06       Impact factor: 5.571

3.  Microparticles for inhalational delivery of antipseudomonal antibiotics.

Authors:  Michael D Tsifansky; Yoon Yeo; Oleg V Evgenov; Evangelia Bellas; John Benjamin; Daniel S Kohane
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

4.  Method of evaluating effects of antibiotics on bacterial biofilm.

Authors:  B L Prosser; D Taylor; B A Dix; R Cleeland
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 5.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

6.  Levofloxacin pharmacokinetics in adult cystic fibrosis.

Authors:  Carlton K K Lee; Michael P Boyle; Marie Diener-West; Lois Brass-Ernst; Michelle Noschese; Pamela L Zeitlin
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

7.  Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats.

Authors:  Cynthia Bosquillon; Véronique Préat; Rita Vanbever
Journal:  J Control Release       Date:  2004-04-28       Impact factor: 9.776

Review 8.  Aerosolized dornase alpha (rhDNase) in cystic fibrosis.

Authors:  R D Bates; M C Nahata
Journal:  J Clin Pharm Ther       Date:  1995-12       Impact factor: 2.512

Review 9.  Aerosol antibiotics in cystic fibrosis.

Authors:  David E Geller
Journal:  Respir Care       Date:  2009-05       Impact factor: 2.258

10.  Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.

Authors:  J M Zahm; S Girod de Bentzmann; E Deneuville; C Perrot-Minnot; A Dabadie; F Pennaforte; M Roussey; S Shak; E Puchelle
Journal:  Eur Respir J       Date:  1995-03       Impact factor: 16.671

View more
  11 in total

1.  A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.

Authors:  Manon F Pritchard; Lydia C Powell; Alison A Jack; Kate Powell; Konrad Beck; Hannah Florance; Julian Forton; Philip D Rye; Arne Dessen; Katja E Hill; David W Thomas
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

3.  Epithelial profiling of antibiotic controlled release respiratory formulations.

Authors:  Hui Xin Ong; Daniela Traini; Mary Bebawy; Paul Michael Young
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

4.  Battling with environments: drug delivery to target tissues with particles and functional biomaterials.

Authors:  Yoon Yeo
Journal:  Ther Deliv       Date:  2010-12

Review 5.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

6.  Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug delivery.

Authors:  Ju Du; Ibrahim M El-Sherbiny; Hugh D Smyth
Journal:  AAPS PharmSciTech       Date:  2014-07-31       Impact factor: 3.246

Review 7.  Cystic fibrosis - a multiorgan protein misfolding disease.

Authors:  Douglas Fraser-Pitt; Deborah O'Neil
Journal:  Future Sci OA       Date:  2015-09-01

8.  Effects of Inhalable Microparticles of Seonpyejeongcheon-Tang in an Asthma Mouse Model: - Effects of Microparticles of SJT.

Authors:  Won-Kyung Yang; Chul-Hwa Lee; Min-Hee Kim; Seung-Hyeong Kim; Hae-Yoon Choi; Yoon Yeo; Yang-Chun Park
Journal:  J Pharmacopuncture       Date:  2016-12

9.  Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols.

Authors:  Hyo-Jung Lee; Ji-Hyun Kang; Hong-Goo Lee; Dong-Wook Kim; Yun-Seok Rhee; Ju-Young Kim; Eun-Seok Park; Chun-Woong Park
Journal:  Drug Des Devel Ther       Date:  2016-12-13       Impact factor: 4.162

Review 10.  Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.

Authors:  John Lam; Steven Vaughan; Michael D Parkins
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2013-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.